Developing a vaccine to prevent RSV, a cause of serious respiratory infections in infants (children)

Respiratory syncytial virus (RSV) is a highly infectious respiratory virus that infects the lungs and breathing passages. In children RSV infection typically occurs at least once a year and in adults every 3-5 years during the winter season. RSV is considered to be one of the most important causes of serious acute respiratory illness in infants and children under 5 years of age. Children usually experience mild to moderate cold-like symptoms and recover in a few days to a week. However, some infants require hospital admission and sometimes need a ventilator to help with breathing.

Babies born Early Antibody Response to Men B (BEAR Men B)

We are working with Public Health England and a group of UK hospitals to investigate how well the new Men B vaccine, Bexsero®, works in premature babies. This vaccine is given to all babies in the UK to provide protection against one type of bacteria which causes meningitis (inflammation of the lining of the brain) and septicaemia (blood poisoning).

Why are we doing this study?

Understanding RSV: Severe disease and the long term consequences

Oxford Vaccine Group are currently inviting children under 12 months of age to take part in a study which will help us learn more about the virus that most commonly causes coughs, colds and chest infections in young children and can sometimes cause children to be so unwell they have to be admitted to hospital.

More than half of children will be infected with the virus, called Respiratory Syncytial Virus (RSV) in their first year of life, mostly during the winter.

Burden of RSV Disease

Some facts about RSV disease (respiratory syncytial virus):

RSV is a virus;

  • it causes coughs, colds and chest infections
  • is responsible for around 1 in 6 hospital admissions for infants  in the UK
  • The second largest worldwide cause of deaths in children between one month and 1 year of age, most are in Asia and Africa

What do we want to do?

We would like to identify 2000 babies from birth and follow them up to see if any become unwell with RSV disease

ImmunoglobuliN in the Treatment of Encephalitis

The IgNiTE Study

A study testing a new treatment for children with encephalitis.

The Department of Paediatrics at the University of Oxford, in collaboration with NHS Trusts across the United Kingdom, is currently running a study for hospitalised children with encephalitis. The study will assess whether a treatment called intravenous immunoglobulin (IVIg, sometimes referred to as antibody treatment) has any benefit for these children when given early during the hospital admission.

Subscribe to Trials - Oxford Vaccine Group RSS